# SELLAS Life Sciences Group, Inc. (SLS) stock news and updates

As of November 17, 2026. Source: https://www.clearthesis.ai/updates/SLS

## Our view on the SELLAS Life Sciences Group, Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/SLS

## Latest updates on SELLAS Life Sciences Group, Inc.

### Phase 3 REGAL trial for leukemia vaccine meets main goal

*November 17, 2026 · news · significance: major · signal: positive*

The Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary goal, showing that the vaccine helped patients with acute myeloid leukemia (AML) live longer. Patients receiving GPS had a median survival of 24 months compared to about 15 months for those on standard treatments. This represents a 41 percent reduction in the risk of death. This is the most critical milestone in the company's history. As a clinical-stage biotech with no products on the market, the entire business was essentially a bet on this specific trial. These results provide the data needed to seek regulatory approval, which would transform the company from a research firm into a commercial drug maker.

Sources: [GlobeNewsWire](https://www.globenewswire.com/news-release/2026/11/17/3404429/0/en/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunotherapeutic-cancer-vaccine-galinpepimut-s-gps-demonstrated-a-statistically-significant-and-cl.html)

### Third quarter results and cash update

*November 12, 2026 · earnings · significance: major · signal: neutral*

The company reported a quarterly loss of 5 cents per share, which matched what analysts expected. More importantly for a biotech firm with no revenue, it ended September with about 135 million dollars in cash. This is a significant increase from the 72 million dollars it held at the end of last year. Management confirmed that the final analysis of the pivotal REGAL trial is expected this month. They also noted that a separate Phase 2 trial for their other drug candidate, SLS009, is fully enrolled with early data expected before the end of the year. For now, the company has enough cash to reach these key clinical milestones.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000021/0001390478-26-000021-index.htm)

### Positive Phase 2 data for SLS009 in high-risk leukemia

*November 4, 2026 · news · significance: notable · signal: positive*

The company will present data showing that its drug candidate SLS009, when used with other therapies, helped patients with high-risk acute myeloid leukemia (AML) who had failed previous treatments. Patients with specific genetic mutations saw response rates of 54 to 57 percent, and they lived significantly longer than the historical average for this patient group. While the Phase 3 REGAL trial is the main focus for the company, these results suggest SLS009 could be a valuable second asset. It targets patients who currently have very few effective options, which could give the company another path to growth if the drug continues to perform well in larger studies.

Sources: [GlobeNewsWire](https://www.globenewswire.com/news-release/2026/11/04/3395382/0/en/sellas-life-sciences-to-present-positive-phase-2-data-demonstrating-encouraging-response-and-survival-outcomes-with-sls009-combination-in-high-risk-aml-at-ash-2026.html)

## SELLAS Life Sciences Group, Inc. earnings

In Q3 2026, reported on November 12, 2026, SELLAS Life Sciences Group, Inc. posted earnings of $-0.05 per share against $-0.05 expected.

The next earnings report is expected on March 25, 2027. Analysts expect $-0.05 per share. Revenue is expected around $36.1 million.

What to watch: The cash runway, which shows how many months of funding the company has left before it needs to raise more money to keep its trials running.

## What's ahead for SELLAS Life Sciences Group, Inc.

- March 25, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/SLS
